MannKind soars as FDA panel backs its inhaled insulin product

(Reuters) - MannKind Corp's shares doubled on Wednesday, after an advisory committee to the U.S. health regulator recommended approval of the drug developer's inhaled insulin treatment.

via Reuters: Health News Read More Here..